Shire PLC (ADR)  

(Public, NASDAQ:SHPG)   Watch this stock  
Find more results for NASDAQ:SHPGY
159.90
+8.90 (5.89%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 153.66 - 160.09
52 week 147.60 - 270.63
Open 154.12
Vol / Avg. 3.04M/2.52M
Mkt cap 33.05B
P/E 23.64
Div/yield 0.66/0.85
EPS 6.76
Shares 600.60M
Beta 1.04
Inst. own 7%
Apr 29, 2016
Q1 2016 Shire PLC Earnings Release Add to calendar
Apr 28, 2016
Shire PLC Annual Shareholders Meeting Add to calendar
Apr 27, 2016
Shire PLC Annual Shareholders Meeting (Estimated) - 9:45AM EDT - Add to calendar
Feb 11, 2016
Full Year 2015 Shire PLC Earnings Call
Feb 11, 2016
Full Year 2015 Shire PLC Earnings Release
Jan 12, 2016
Shire PLC at JPMorgan Healthcare Conference (Q&A Session)
Jan 12, 2016
Shire PLC at JPMorgan Healthcare Conference
Dec 3, 2015
Shire PLC at Deutsche Bank dbAccess Pharmaceutical Corporate Day
Dec 1, 2015
Shire PLC at Piper Jaffray Healthcare Conference
Nov 18, 2015
Shire PLC at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 16.55% 20.88%
Operating margin 20.78% 22.12%
EBITD margin - 33.97%
Return on average assets 6.69% 8.86%
Return on average equity 11.73% 14.47%
Employees 5,016 -
CDP Score - 91 B

Address

5 Riverwalk Citywest Business Campus, Dublin 24
DUBLIN,
Ireland
+353-1-4297700 (Phone)
+353-1-4297701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Shire plc is a biopharmaceutical company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. The Company commercializes its products in the areas of Neuroscience, Gastrointestinal (GI), Rare Diseases and Other therapeutic areas. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), BUCCOLAM, LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), REPLAGAL (agalsidase alfa), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), FOSRENOL (lanthanum carbonate), XAGRID/ AGRYLIN (anagrelide hydrochloride) and PLENADREN (modified release hydrocortisone).

Officers and directors

Flemming Ornskov M.D. Chief Executive Officer, Executive Director
Age: 57
Bio & Compensation  - Reuters
Jeffrey Poulton Chief Financial Officer, Director
Age: 47
Bio & Compensation  - Reuters
Ginger Gregory Chief Human Resource Officer
Bio & Compensation  - Reuters
Mark J. Enyedy Interim General Counsel, Head of Corporate Development
Age: 51
Bio & Compensation  - Reuters
Phil J. Vickers Head of Research and Development
Age: 55
Bio & Compensation  - Reuters
Susan Saltzbart Kilsby Non-Executive Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
David J. Kappler Senior Independent Non-Executive Deputy Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Olivier Bohuon Non-Executive Director
Age: 56
Bio & Compensation  - Reuters
Sara Mathew Non-Executive Director
Age: 60
Bio & Compensation  - Reuters
Dominic Blakemore Non-Executive Independent Director
Age: 46
Bio & Compensation  - Reuters